Round Hill Asset Management Has $4.20 Million Stock Position in Novo Nordisk A/S $NVO

Round Hill Asset Management raised its position in Novo Nordisk A/S (NYSE:NVO) by 32.8% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 75,725 shares of the company’s stock after buying an additional 18,686 shares during the period. Novo Nordisk A/S accounts for 2.8% of Round Hill Asset Management’s investment portfolio, making the stock its 10th biggest holding. Round Hill Asset Management’s holdings in Novo Nordisk A/S were worth $4,202,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. True Wealth Design LLC lifted its holdings in Novo Nordisk A/S by 209.8% during the third quarter. True Wealth Design LLC now owns 443 shares of the company’s stock worth $25,000 after acquiring an additional 300 shares during the period. Guerra Advisors Inc bought a new stake in Novo Nordisk A/S in the third quarter worth about $25,000. Strengthening Families & Communities LLC purchased a new position in Novo Nordisk A/S in the third quarter valued at about $30,000. NewSquare Capital LLC grew its position in shares of Novo Nordisk A/S by 174.1% during the 2nd quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock valued at $31,000 after acquiring an additional 282 shares during the period. Finally, Allianz SE increased its stake in shares of Novo Nordisk A/S by 70.0% during the 3rd quarter. Allianz SE now owns 578 shares of the company’s stock worth $32,000 after purchasing an additional 238 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Company started executing a 2026 share repurchase programme (part of an overall up-to-DKK15bn programme) — buybacks typically support the share price by reducing float and returning capital to shareholders. Novo Nordisk A/S – share repurchase programme
• Positive Sentiment: Large manufacturing investment — Novo Nordisk will invest €432m (~$506m) to expand its Athlone, Ireland tablet facility, adding capacity for oral GLP‑1 medicines (a strategic growth area). This supports future revenue and supply for oral products. Novo Nordisk announces more than 400 million euro expansion in its manufacturing facility in Athlone, Ireland
• Positive Sentiment: R&D/partnership push for oral biologics — a multi‑billion DKK partnership with Vivtex targets next‑generation oral delivery for obesity/diabetes treatments, supporting pipeline diversification beyond injectables. Novo Nordisk Eyes Oral GLP 1 Growth With Vivtex And Irish Expansion
• Positive Sentiment: Regulatory win — FDA expanded indications for once‑weekly Sogroya (growth hormone), extending addressable market and adding near‑term revenue upside for that franchise. Novo Nordisk A/S (NVO) Announces FDA Approval of Three New Indications for Sogroya
• Neutral Sentiment: Company provided progress details on the 2026 buyback under EU “Safe Harbour” rules — procedural update that clarifies execution but doesn’t change programme size or timing materially. Novo Nordisk Details Progress of 2026 Share Buyback Programme
• Negative Sentiment: Goldman Sachs kept a “neutral” rating but slashed the price target from $63 to $41, signaling weaker near‑term earnings/valuation expectations and weighing on sentiment. Goldman Sachs rating/price target note
• Negative Sentiment: Press coverage highlights concerns about slowing growth and broader economic impact as Novo Nordisk’s GLP‑1 boom moderates, which can pressure momentum investors and multiples. Denmark’s fat jab champion is slimming down the whole economy

Wall Street Analyst Weigh In

NVO has been the topic of several research analyst reports. TD Cowen reiterated a “buy” rating on shares of Novo Nordisk A/S in a research note on Tuesday, February 3rd. CICC Research started coverage on Novo Nordisk A/S in a research note on Friday, January 9th. They issued an “outperform” rating and a $73.50 target price on the stock. BMO Capital Markets reiterated a “market perform” rating on shares of Novo Nordisk A/S in a research note on Thursday, February 5th. Weiss Ratings raised shares of Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, February 5th. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $41.00 price objective (down from $63.00) on shares of Novo Nordisk A/S in a report on Monday. Five research analysts have rated the stock with a Buy rating, seventeen have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $54.21.

Novo Nordisk A/S Trading Down 0.3%

Shares of Novo Nordisk A/S stock opened at $37.50 on Monday. The company’s 50-day moving average price is $52.75 and its 200-day moving average price is $52.88. The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61. Novo Nordisk A/S has a 12-month low of $37.31 and a 12-month high of $91.90. The company has a market cap of $167.42 billion, a price-to-earnings ratio of 10.81 and a beta of 0.74.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, topping analysts’ consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The business had revenue of $12.43 billion for the quarter, compared to analyst estimates of $11.97 billion. On average, equities analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The firm also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be paid a dividend of $1.2751 per share. The ex-dividend date of this dividend is Monday, March 30th. This represents a yield of 541.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 23.63%.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.